All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the main advances in patient care that we are seeing with novel agents for leukemia?

During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Guru Subramanian Guru Murthy, Medical College of Wisconsin, Milwaukee, US. We asked, What are the main advances in patient care that we are seeing with novel agents for leukemia?

What are the main advances in patient care that we are seeing with novel agents for leukemia?

Guru Murthy evaluates data on new targeted agents for ALL, including blinatumomab, an anti-CD19 bispecific antibody, and inotuzumab, an anti-CD22 antibody-drug conjugate. He also focuses on a new treatment for Philadelphia chromosome-positive ALL, using trial data investigating a chemotherapy-free approach that combined blinatumomab and ponatinib, a tyrosine kinase inhibitor (TKI). 

 

Share: